Hostname: page-component-8448b6f56d-m8qmq Total loading time: 0 Render date: 2024-04-23T10:26:23.092Z Has data issue: false hasContentIssue false
  • English
  • Français

El síndrome deficitario en la esquizofrenia: implicaciones para el tratamiento de los síntomas negativos

Published online by Cambridge University Press:  12 May 2020

C. Arango ,
R.W. Buchanan ,
B. Kirkpatrick  and
W.T. Carpenter
C. Arango
Affiliation:
Servicio de Psiquiatría, Hospital General “Gregorio Marañón”, C/Ibiza 43, 28079Madrid, España
R.W. Buchanan
Affiliation:
Servicio de Psiquiatría, Hospital General “Gregorio Marañón”, C/Ibiza 43, 28079Madrid, España
B. Kirkpatrick
Affiliation:
Servicio de Psiquiatría, Hospital General “Gregorio Marañón”, C/Ibiza 43, 28079Madrid, España
W.T. Carpenter
Affiliation:
Servicio de Psiquiatría, Hospital General “Gregorio Marañón”, C/Ibiza 43, 28079Madrid, España
Get access

Resumen

Las manifestaciones psicopatológicas de la esquizofrenia se agrupan en tomo a varios dominios de síntomas. Uno de estos dominios son los síntomas negativos. Hemos definido el síndrome deficitario como una entidad patológica caracterizada por la presencia de síntomas negativos duraderos primarios. Un enfoque en lo s síntomas negativos primarios demuestra que los subgrupos de esquizofrenia deficitaria y no deficitaria difieren en los rasgos clínicos, los hallazgos de imágenes neurales asociadas, las medidas neuropsicológicas y neurológicas, el patrón de factores de riesgo y los perfiles de respuesta farmacológica. En el presente artículo, nos centramos en la importancia de la distinción entre los síntomas negativos primarios y secundarios para la investigación fisiopatológica. El desarrollo y comprensión mecanicista de fármacos contra los síntomas negativos puede ser informativo con respecto a la fisiopatología de los síntomas negativos primarios. Aunque los nuevos antipsicóticos son efectivos para los síntomas negativos secundarios, no han mostrado eficacia para el síndrome deficitario y parece que se requieren nuevos mecanismos de acción farmacológica para estudiar este aspecto del síndrome patológico. La pérdida de experiencias humanas inapreciables y la asociación con mala evolución funcional a largo plazo justifica un esfuerzo enfocado y dedicado a descubrir las causas y los tratamientos de este aspecto distintivo de la esquizofrenia.

Type
Artículo original
Information
European Psychiatry (Ed. Española) , Volume 11 , Issue 4 , May 2004 , pp. 219 - 224
Copyright
Copyright © European Psychiatric Association 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografía

Dementia praecox or the Group of Schizophrenias. New York, NY: International Universities Press; 1950.Google Scholar
Carpenter, W.T. Jr, Arango, C., Kirkpatrick, B., Buchanan, R.W.Deficit psychopathology and a paradigm shift in schizophrenia research. Biol Psychiatry 1999;46:352–60.CrossRefGoogle Scholar
Carpenter, W.T. Jr, Buchanan, R.W., Kirkpatrick, B., Tamminga, C., Wood, F., Stroog inference, theory testing, and the neuroanatomy of schizophrenia. Arch Gen Psychiatry 1993;50:825–31.CrossRefGoogle ScholarPubMed
Kirkpatrick, B., Buchanan, R.W., Ross, D.E., Carpenter, W.T. Jr, A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry 2001;58:165–71.CrossRefGoogle ScholarPubMed
Kraepelin, E.Dementia praccox and paraphrenia. New York: Krie- ger; 1971: [Original work published 1919].Google Scholar
Rado, S.Psychoanalysis of behavior: collected-papers. New York: Grane & Stratton; 1956.Google Scholar
Meehl, P.E.Schizotaxia, schizotypy, and schizophrenia. Am Psychol 1962;17:827–38.CrossRefGoogle Scholar
Jaspers, K.General psychopathology. 7th ed. Manchester: Manchester University Press; 1963 [Hoenig, J., Hamilton, M.W., Trans.].Google Scholar
Carpenter, W.T. Jr, Bartko, J.J., Carpenter, C.L., Strauss, J.S.Another view of schizophrenia subtypes. A report from the international pilot study of schizophrenia. Arch Gen Psychiatry 1976;33:508–16.CrossRefGoogle ScholarPubMed
Carpenter, W.T. Jr, Strauss, J.S.The prediction of outcome in schizophrenia. IV: eleven-year follow-up of the Washington IPSS cohort. J Nerv Ment Dis 1991;179:517–25.CrossRefGoogle ScholarPubMed
Buchanan, R.W., Carpenter, W.T., Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia. J Nerv Ment Dis 1994;182:193-204.CrossRefGoogle Scholar
Andreasen, N.C., Olsen, S., Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry 1982;39:789–94.CrossRefGoogle Scholar
Crow, TJ., Molecular pathology of schizophrenia: more than one disease process? Br Med J 1980;280:66–8.CrossRefGoogle ScholarPubMed
Carpenter, W.T. Jr, Heinrichs, D.W., Wagman, A.M.I., Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988;145:578–83.Google ScholarPubMed
Kirkpatrick, B., Buchanan, R.W., McKenney, P.D., Alphs, L.D., Carpenter, W.T. Jr, The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res 1989;30(2):119–23.CrossRefGoogle Scholar
Overall, J.E., Gorham, D.R., The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.CrossRefGoogle Scholar
Andreasen, N.C., The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry 1989;7(Suppl):49-58.CrossRefGoogle Scholar
Kay, S.R., Fiszbein, A., Opler, L.A., The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:26176.CrossRefGoogle Scholar
Blyler, C.R., Gold, J.M., Cognitive effects of typical antipsychotic treatment: another look. In: Sharma, T., Harvey, P.D., editors. Cognition in schizophrenia: impairments, importance, and treatment strategies. New York; Oxford University Press; 2000. p. 241–65.Google Scholar
Tek, C., Kirkpatrick, B., Buchanan, R.W., A five-year followup study of deficit and nondeficit schizophrenia. Schizophr Res 2001(49):253–60.CrossRefGoogle ScholarPubMed
Tamminga, C.A., Thaker, G.K., Buchanan, R., Kirkpatrick, B., Alphs, L.D., Chase, T.N., et al. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxy-glucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 1992;49(7):522–30.CrossRefGoogle Scholar
Buchanan, R.W., Breier, A., Kirkpatrick, B., Elkashef, A., Munson, R.C., Gellad, F., et al. Structural abnormalities in deficit and nondeficit schizophrenia. Am J Psychiatry 1993;150(1):59-65.Google ScholarPubMed
Quarantelli, M., Larobina, M., Volpe, U., Amati, G., Tedeschi, E., Ciar-miello, A., et al. Stereotaxy-based regional brain volumetry applied to segmentad MRI: validation and results in deficit and nondeficit schizophrenia. Neuroimage 2002;17(1):373–84.CrossRefGoogle ScholarPubMed
Kane, J., Honigfeld, G., Singer, J., Meltzer, H.Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789–96.CrossRefGoogle ScholarPubMed
Conley, R., Richardson, C., Kent, D., Gounaris, C., Zaremba, S., Clozapine response varias in deficit vs non-deficit schizophrenic subjects. Biol Psychiatry 1994;35:746.CrossRefGoogle Scholar
Buchanan, R.W., Breier, A., Kirkpatrick, B., Ball, P., Carpenter, W.T. Jr, Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 1998;155:751–60.Google ScholarPubMed
Kane, J.M., Marder, S.R., Schooler, N.R., Wirshing, W.C., Umbricht, D., Baker, R.W. et al. Clozapine and haloperidol in moderately refractory schizophrenia: a six-month randomized and double-blind comparison. Arch Gen Psychiatry 2001;58:965–72.CrossRefGoogle Scholar
Rosenheck, R., Dunn, L., Peszke, M., Cramer, J., Xu, W., Thomas, J., et al. Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Am J Psychiatry 1999;156:88-93 Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.CrossRefGoogle ScholarPubMed
Taminaga, C., Glutamatergic aspects of schizophrenia. Br J Psychiatry 1999;37(Suppl):12–5.CrossRefGoogle Scholar
Goff, D.C., Tsai, G., Levitt, J., Amito, E., Manoach, D., Schoenfeld, D.A., et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 1999;56(1):21–7.CrossRefGoogle ScholarPubMed
Heresco-Levy, U., Javitt, D.C., Ermilov, M., Mordel, C., Silipo, G., Lichtenstein, M.Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999; 56(1):29-36.CrossRefGoogle ScholarPubMed
Tsai, G., Yang, P., Chung, L.C., Lange, N., Coyle, J.T., D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998;44:1081–9.CrossRefGoogle ScholarPubMed
Tsai, G.E., Yang, P., Chung, L.C., Tsai, I.C., Tsai, C.W., Coyle, J.T., D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry 1999;156(11):1822–5.Google ScholarPubMed
Boyer, P., Lecrubier, Y., Puech, A.J., Dewailly, J., Aubin, F., Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 1995;166:68-72.CrossRefGoogle ScholarPubMed
Paillere-Martinot, M.L., Lecrubier, Y., Martinot, J.L., Aubin, E.Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 1995;152:130–4.Google ScholarPubMed